Loading
Hormonal Regulation and Hypertension / Blood Pressure and Hypertension Studies / Diabetes Treatment and Management · Journal article
Current Cardiology Reports · September 7, 2026
A consensus or society position rather than new primary data.
The 2025 AHA/ACC hypertension guideline retains prior BP targets (<130/80 mmHg) while introducing race-free risk assessment (PREVENT equations), a 7.5% 10-year cardiovascular risk threshold for pharmacologic treatment of stage-1 hypertension, and expanded screening and monitoring practices. The guideline emphasizes implementation of accurate measurement and sustained intensification rather than identification of new drugs, reflecting maturity in pharmacologic evidence.
Multisociety clinical practice guideline. General hypertensive population across multiple clinical subgroups including diabetes and older adults.
Blood pressure treatment goal remains <130/80 mmHg, consistent with 2017 guideline Introduction of PREVENT equations for race-free cardiovascular risk assessment 7.5% 10-year risk threshold adopted to guide pharmacologic treatment of stage-1 hypertension
7.5% 10-year risk threshold adopted to guide pharmacologic treatment of stage-1 hypertension
Clinicians should adopt the PREVENT equations for race-free risk stratification when deciding whether to initiate pharmacologic therapy in stage-1 hypertension. The guideline emphasizes that implementation challenges—accurate measurement, timely intensification, and sustained follow-up—are now the limiting factors rather than drug efficacy, requiring systems-based approaches to hypertension care delivery.
This is an official multisociety hypertension guideline from the AHA/ACC that synthesizes evidence across populations and provides clinical recommendations for practice.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should adopt the PREVENT equations for race-free risk stratification when deciding whether to initiate pharmacologic therapy in stage-1 hypertension. The guideline emphasizes that implementation challenges—accurate measurement, timely intensification, and sustained follow-up—are now the limiting factors rather than drug efficacy, requiring systems-based approaches to hypertension care delivery.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This review examines the 2025 American Heart Association/American College of Cardiology multisociety hypertension guideline, placing its recommendations in historical context and evaluating the supporting evidence across major clinical populations. The 2025 guideline retains the 2017 blood pressure categories and treatment goal of less than 130/80 mmHg but introduces the race-free PREVENT equations, uses a 7.5% 10-year risk threshold to guide pharmacologic treatment of stage-1 hypertension, and encourages systolic blood pressure below 120 mmHg in selected high-risk patients. Additional updates include single-pill combination therapy for stage-2 hypertension, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio measurement, removal of race-based drug selection, and cautious incorporation of renal denervation. Recent trials strengthen the evidence for intensive lowering, including in diabetes and older adults. The 2025 guideline advances a risk-based, measurement-dependent approach. The principal challenge is no longer identifying effective treatments but delivering accurate measurement, timely intensification, and sustained follow-up at scale.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.